We are the Private Sector Constituency to the Stop TB Partnership (PSC). We are a private sector coalition leveraging our shared resources and capabilities to fight the tuberculosis epidemic.
Tuberculosis is an ancient, infectious airborne disease, which has killed 2 billion people in the last 200 years. Since the 1940s, the number of cases of tuberculosis in developed countries has plunged, leading some to believe that tuberculosis had been eradicated, or that the disease is being controlled. However, progress has been uneven, and many communities – particularly those in still-developing countries – are at risk of being left behind. Complicating matters, the emergence of drug - resistant tuberculosis strains has slowed progress against the disease, making it more dangerous for those in developed and developing countries alike.
Tuberculosis is the only major airborne
epidemic exhibiting drug-resistance remaining:
in 2017, 10 million people fell ill with tuberculosis,
and 1.6 million of those infected died from
the disease. Even with treatment, only
approximately half of the people who contract
the disease are cured.
Drug-resistant tuberculosis is expected to cost the global economy US$17 trillion by 2050 if it remains unchecked; work
absences due to drug-resistant tuberculosis cost the global GDP over US$3 billion in 2018 alone. And, because of drug
resistant strains, tuberculosis poses a major threat to global health security. Deaths attributable to antimicrobial resistance
could rise to 10 million annually by 2050, with 2.5 million of those deaths caused by drug-resistant tuberculosis.*
making the case for private sector’s engagement
Engaging the private sector is critical to address TB in the highest burden countries
Our members include healthcare organizations, pharmaceutical, diagnostic, and technology companies.The companies in the PSC are committed to this cause in recognition of the scale of the epidemic, and because we believe we are well placed to use our knowledge, skills and products to support tuberculosis diagnosis and treatment. Our businesses – and the communities we serve – are dramatically impacted by the tuberculosis epidemic. Many of our members operate in high TB burden countries such as China, Nigeria, Russia, and South Africa, or anticipate expansion to these markets.
We are committed to saving lives, supporting the global economy, and bolstering global health security.
Our Priorities
01
Data & Diagnostics
Our objective:
Enhance and streamline data generation and use through integration of existing echnologies and new partnerships
02
Healthy workplaces
Our objective:
Help businesses create world-class workplace health programs in high-TB risk industries for employees and communities
03
Advocacy & Communication
Our objective:
Shine a spotlight on TB through a coordinated advocacy campaign and explore new engagement models to spread awareness and mobilize funds